Synthesis and Biological Profile of Omaveloxolone: The Cornerstone for Friedreich Ataxia Treatment
Open Access
- 7 October 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9747
Abstract
This review provides a comprehensive overview of the therapeutic potential of omaveloxone (OMA) for the treatment of Friedreich’s ataxia (FA), along with an analysis of the historical development and current status of the synthetic strategies for OMA production. OMA activates the nuclear factor-2-(erythroid-2)-related (Nrf2) pathway in vitro and in vivo, in both animal models and humans. The Nrf2 pathway plays a crucial role in the cellular response to oxidative stress. Furthermore, OMA has been shown to mitigate mitochondrial dysfunction, restore redox homeostasis and downregulate nuclear factor-κB (NF-κB), a key mediator of inflammatory responses. Through these mechanisms, OMA contributes to tissue protection and inflammation reduction in patients with FA. The review also highlights future perspective, focusing on the challenges associated with OMA reprofiling through innovative drug delivery approaches and its potential repurposing for diseases beyond FA.Keywords
Funding Information
- Progetto Pharma-HUB-Hub per il riposizionamento di farmaci nelle malattie rare del sistema nervoso in età pediatrica (CUP J43C22000500006-T4-AN-04)
This publication has 63 references indexed in Scilit:
- Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modelingCPT: Pharmacometrics & Systems Pharmacology, 2024
- Targeted-lung delivery of bardoxolone methyl using PECAM-1 antibody-conjugated nanostructure lipid carriers for the treatment of lung inflammationBiomedicine & Pharmacotherapy, 2024
- New Horizons of Model Informed Drug Development in Rare Diseases Drug DevelopmentClinical Pharmacology & Therapeutics, 2024
- Autocatalytic, Brain Tumor‐Targeting Delivery of Bardoxolone Methyl Self‐Assembled Nanoparticles for Glioblastoma TreatmentSmall Science, 2024
- Synthesis and clinical application of new drugs approved by FDA in 2023European Journal of Medicinal Chemistry, 2024
- Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history dataAnnals of Clinical and Translational Neurology, 2023
- Three-armed RGD-decorated starPLA-PEG nanoshuttle for docetaxel deliveryMaterials Science and Engineering: C, 2022
- Oleanane triterpenoids in the prevention and therapy of breast cancer: current evidence and future perspectivesPhytochemistry Reviews, 2014
- Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skinArchives of Dermatological Research, 2013
- Fruit cuticular waxes as a source of biologically active triterpenoidsPhytochemistry Reviews, 2012